BML scores in Exercise 1 (40 knees in the injection cohort and 40 matched knees in the control cohort) and Exercise 2 (16 knees)
| BML scores: mean (SD) | ||||||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | Change | SDC (% of max) | p Value | SRM | |
| EXERCISE 1 (1-year follow-up) | ||||||
| KIMRISS (injection) | 26.7 (21.6) | 33.7 (26.4) | 7.0 (20.1) | 24.6 (3.2%) | 0.876* | |
| KIMRISS (control) | 15.6 (17.2) | 21.9 (28.6) | 6.4 (15.4) | |||
| MOAKS (injection) | 4.7 (2.5) | 5.0 (2.5) | 0.3 (1.7) | 2.3 (5.1%) | 0.507* | |
| MOAKS (control) | 3.1 (2.3) | 3.6 (3.0) | 0.5 (1.6) | |||
| EXERCISE 2 (12-week follow-up) | ||||||
| KIMRISS | 37.3 (36.7) | 29.8 (34.9) | −7.5 (10.9) | 15.1 (1.9%) | 0.015† | −0.69 |
| MOAKS | 6.3 (0.9) | 6.1 (0.8) | −0.2 (0.4) | 0.55 (1.2%) | 0.625† | −0.12 |
All readings are the average of two expert reader scores.
Bold=statistically significant.
*For the difference in BML change scores between injection and control groups.
†For the difference between baseline and follow-up BML scores.
BML, bone marrow lesions; SDC, smallest detectable change; SRM, standardised response mean, not calculated for Exercise 1 (not meaningful for observational data).